Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Feb 2007
Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
To investigate rectal morbidity after I-125 prostate brachytherapy and to analyze predictive factors of rectal morbidity. ⋯ Manifestations of rectal morbidity are acceptable events after I-125 prostate brachytherapy. Rectal dose-volume histogram for the brachytherapy is a predictive method for assessing the risk of developing grade 2 rectal bleeding. Delivery of the rectal dose should not exceed 160 Gy in order to avoid rectal complications.
-
Jpn. J. Clin. Oncol. · Feb 2007
Initial experience with the quality assurance program of radiation therapy on behalf of Japan Radiation Oncology Group (JAROG).
We evaluated the efficacy of our quality assurance (QA) program of radiation therapy (RT) in a prospective phase II study. This is the first description of the experience of the Japan Radiation Oncology Group (JAROG) with this program. ⋯ This is the first report with regard to the QA program in MALT lymphoma. We demonstrated that our QA program was simple and inexpensive. We also confirmed that the radiation oncologists in Japan adhered closely to the protocol guidelines.
-
Jpn. J. Clin. Oncol. · Dec 2006
Randomized Controlled Trial Comparative StudyA randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
To investigate the optimal treatment of locally advanced prostate cancer, a prospective randomized trial was conducted to compare radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy. ⋯ For the treatment of patients with locally advanced prostate cancer, when combined with endocrine therapy, either radical prostatectomy or external beam radiotherapy demonstrated favorable long-term outcomes. The radiation dose of 60-70 Gy might not be enough for the local treatment of locally advanced prostate cancer.
-
Jpn. J. Clin. Oncol. · Dec 2006
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Pegylated liposomal doxorubicin (PLD, JNS002) is a formulation of doxorubicin encapsulated polyethylene-glycol coated liposomes with prolonged circulation time and unique toxicity profile. This phase 1 study was aimed at investigating the maximum tolerated dose (MTD), recommended dose, toxicity, pharmacokinetics, and antitumor activity in Japanese patients with solid tumors. ⋯ The recommended dose for phase 2 clinical studies of PLD in Japanese patients was 50 mg/m(2) every 4 weeks. The encouraging results prompted us to plan a subsequent clinical study of PLD against ovarian cancer.
-
Jpn. J. Clin. Oncol. · Nov 2006
Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Imatinib has been found to be effective in the treatment of patients with gastrointestinal stromal tumors (GIST). We sought to evaluate the clinical outcome of imatinib interruption in GIST patients who had achieved stable disease (SD) or showed better response to imatinib therapy. ⋯ In GIST patients controlled with imatinib, treatment might be interrupted, at least temporarily, when clinically warranted.